FBXO22 Antibodies

Santa Cruz Biotechnology delivers a wide array of FBXO22 monoclonal antibodies for research focused on understanding FBXO22 protein functions. FBXO22 monoclonal antibodies are validated for multiple applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). FBXO22 is a member of the F-box protein family, which plays a central role in the ubiquitin-proteasome pathway, a key mechanism for protein degradation and regulation within the cell. FBXO22 is involved in the modulation of various cellular processes, including cell cycle progression and signal transduction, making it essential for maintaining cellular homeostasis. Research has shown that FBXO22 has significant implications in various diseases, including cancer and neurodegenerative disorders. Investigating FBXO22 expression and interactions can reveal new therapeutic targets and pathways. Understanding FBXO22's role in protein degradation pathways opens new possibilities for drug development and treatment strategies. FBXO22 studies continue to uncover novel mechanisms in cellular regulation and disease progression. Santa Cruz Biotechnology monoclonal antibodies enable researchers worldwide to advance scientific understanding of cellular biology and disease mechanisms.